Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WLF Appeals Court Decision Leaves Free Speech Question Open

Executive Summary

FDA's ability to introduce sponsor dissemination of off-label reprints as evidence in enforcement action litigation may be the next item open for constitutional questioning, following the Feb. 11 dismissal of Washington Legal Foundation v. Henney by the Washington D.C. appeals court.

You may also be interested in...



FDA’s TV Ad Review Is Unconstitutional, PhRMA Says, Or Maybe Should Be A Reg

A draft guidance that outlines six categories of drug ads FDA wants submitted for prior review is a violation of advertisers’ free speech rights, the industry group argues. Other comments float a storyboard compromise.

Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground

A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content

Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground

A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content

Related Content

UsernamePublicRestriction

Register

PS035614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel